Literature DB >> 10336539

Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers.

D J Walker1, J P Zacny.   

Abstract

The subjective, psychomotor, and physiological effects of three opioid mu-receptor agonists were studied in healthy volunteers using a cumulative-dosing procedure. Sixteen volunteers with no history of drug abuse received i.v. injections of saline (SAL), morphine (MOR), hydromorphone (HM), or meperidine (MEP) in a randomized double-blind crossover design. Subjects received 1 injection/h for the first 4 h, and a 3-h recovery period followed. SAL was injected first during each session, then SAL or increasing doses of each drug were administered every hour for the next 3 h. The absolute doses per injection were MOR: 2.5, 5, and 10 mg/70 kg; HM: 0.33, 0.65, and 1.3 mg/70 kg; and MEP: 17.5, 35, and 70 mg/70 kg. These injections resulted in cumulative doses of MOR: 2.5, 7.5, and 17.5; HM: 0.33, 0.98, and 2.28; and MEP: 17.5, 52.5, and 122.5 mg/70 kg. Subjects completed mood forms and psychomotor tests, and physiological measures were recorded at various times after each injection and during recovery. MEP tended to produce the most intense effects immediately after drug injection, which dissipated rapidly. MOR produced the mildest effects but was associated with unpleasant side effects during recovery and after the session. HM's effects were stronger than MOR's, and the recovery from HM was slower than with MEP. None of the opioids produced consistent effects that are typically associated with abuse liability. Orderly dose-response functions suggested that our cumulative-dosing procedure is an efficient way of determining dose-response functions for multiple opioids within the same subjects within the same study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10336539

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Opioid treatment of experimental pain activates nuclear factor-κB.

Authors:  Peggy Compton; Charles Griffis; Elizabeth Crabb Breen; Matthew Torrington; Ryan Sadakane; Eshetu Tefera; Michael R Irwin
Journal:  J Opioid Manag       Date:  2015 Mar-Apr

2.  Does preoperative risk for delirium moderate the effects of postoperative pain and opiate use on postoperative delirium?

Authors:  Jacqueline M Leung; Laura P Sands; Eunjung Lim; Tiffany L Tsai; Sakura Kinjo
Journal:  Am J Geriatr Psychiatry       Date:  2013-05-06       Impact factor: 4.105

3.  The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.

Authors:  Frank Fliegert; Burkhard Kurth; Karin Göhler
Journal:  Eur J Clin Pharmacol       Date:  2005-05-20       Impact factor: 2.953

4.  Effects of oxycodone on brain responses to emotional images.

Authors:  Margaret C Wardle; Daniel A Fitzgerald; Michael Angstadt; Christine A Rabinak; Harriet de Wit; K Luan Phan
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

5.  The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users.

Authors:  Joshua A Lile; Thomas H Kelly; Lon R Hays
Journal:  Behav Pharmacol       Date:  2010-02       Impact factor: 2.293

6.  Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation.

Authors:  David Philippe; Laurent Dubuquoy; Hervé Groux; Valérie Brun; Myriam Tran Van Chuoï-Mariot; Claire Gaveriaux-Ruff; Jean-Frédéric Colombel; Brigitte L Kieffer; Pierre Desreumaux
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 7.  The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways.

Authors:  Eric L Garland; Brett Froeliger; Fadel Zeidan; Kaitlyn Partin; Matthew O Howard
Journal:  Neurosci Biobehav Rev       Date:  2013-08-26       Impact factor: 8.989

8.  Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone.

Authors:  Jermaine D Jones; Mudassir Mumtaz; Jeanne M Manubay; Shanthi Mogali; Elliana Sherwin; Suky Martinez; Sandra D Comer
Journal:  Pharmacol Biochem Behav       Date:  2019-09-04       Impact factor: 3.533

9.  Does postoperative delirium limit the use of patient-controlled analgesia in older surgical patients?

Authors:  Jacqueline M Leung; Laura P Sands; Sudeshna Paul; Tim Joseph; Sakura Kinjo; Tiffany Tsai
Journal:  Anesthesiology       Date:  2009-09       Impact factor: 7.892

10.  Preventing Delirium at the End of Life: Lessons From Recent Research.

Authors:  Donna B. Greenberg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.